454 related articles for article (PubMed ID: 27312316)
21. Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy.
von Landenberg N; Speed JM; Cole AP; Seisen T; Lipsitz SR; Gild P; Menon M; Kibel AS; Roghmann F; Noldus J; Sun M; Trinh QD
Urol Oncol; 2018 Feb; 36(2):78.e13-78.e19. PubMed ID: 29169845
[TBL] [Abstract][Full Text] [Related]
22. Venous thromboembolism risk in patients receiving neoadjuvant chemotherapy for bladder cancer.
Garas SN; McAlpine K; Ross J; Carrier M; Bossé D; Yachnin D; Mallick R; Cagiannos I; Morash C; Breau RH; Lavallée LT
Urol Oncol; 2022 Aug; 40(8):381.e1-381.e7. PubMed ID: 35581123
[TBL] [Abstract][Full Text] [Related]
23. Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer: a multidisciplinary approach.
Alva AS; Tallman CT; He C; Hussain MH; Hafez K; Montie JE; Smith DC; Weizer AZ; Wood D; Lee CT
Cancer; 2012 Jan; 118(1):44-53. PubMed ID: 21598245
[TBL] [Abstract][Full Text] [Related]
24. The role of neoadjuvant chemotherapy, lymph node dissection, and treatment delay in patients with muscle-invasive bladder cancer undergoing partial cystectomy.
Lenis AT; Fero KE; Ojeaburu L; Lec PM; Golla V; Brisbane W; Leapman MS; Chamie K
Urol Oncol; 2021 Aug; 39(8):496.e17-496.e24. PubMed ID: 33640225
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer.
Li R; Naidu S; Fan W; Rose K; Huelster H; Grass GD; Vosoughi A; Dhillon J; Kim Y; Gupta S; Jain RK; Zhang J; Zemp L; Yu A; Poch MA; Spiess PE; Pow-Sang J; Gilbert SM; Sexton WJ
Urol Oncol; 2023 Nov; 41(11):457.e17-457.e24. PubMed ID: 37880002
[TBL] [Abstract][Full Text] [Related]
26. The Prognostic Value of Tumor Regression Grades Combined With TNM Classification in Patients With Muscle-Invasive Bladder Cancer Who Underwent Neoadjuvant Chemotherapy Followed by Radical Cystectomy.
Gronostaj K; Czech AK; Fronczek J; Drobniak A; Okon K; Chlosta PL; Szczeklik W
Clin Genitourin Cancer; 2019 Dec; 17(6):e1203-e1211. PubMed ID: 31588010
[TBL] [Abstract][Full Text] [Related]
27. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
Słojewski M
Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.
Vetterlein MW; Wankowicz SAM; Seisen T; Lander R; Löppenberg B; Chun FK; Menon M; Sun M; Barletta JA; Choueiri TK; Bellmunt J; Trinh QD; Preston MA
Cancer; 2017 Nov; 123(22):4346-4355. PubMed ID: 28743155
[TBL] [Abstract][Full Text] [Related]
29. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.
Rosenblatt R; Sherif A; Rintala E; Wahlqvist R; Ullén A; Nilsson S; Malmström PU;
Eur Urol; 2012 Jun; 61(6):1229-38. PubMed ID: 22189383
[TBL] [Abstract][Full Text] [Related]
30. Conservative Management Following Complete Clinical Response to Neoadjuvant Chemotherapy of Muscle Invasive Bladder Cancer: Contemporary Outcomes of a Multi-Institutional Cohort Study.
Mazza P; Moran GW; Li G; Robins DJ; Matulay JT; Herr HW; Decastro GJ; McKiernan JM; Anderson CB
J Urol; 2018 Nov; 200(5):1005-1013. PubMed ID: 29787740
[TBL] [Abstract][Full Text] [Related]
31. Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate.
Lavery HJ; Stensland KD; Niegisch G; Albers P; Droller MJ
J Urol; 2014 Apr; 191(4):898-906. PubMed ID: 24300483
[TBL] [Abstract][Full Text] [Related]
32. Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone.
Mertens LS; Meijer RP; Meinhardt W; van der Poel HG; Bex A; Kerst JM; van der Heijden MS; Bergman AM; Horenblas S; van Rhijn BW
BJU Int; 2014 Jul; 114(1):67-74. PubMed ID: 24053889
[TBL] [Abstract][Full Text] [Related]
33. Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a.
May M; Bastian PJ; Brookman-May S; Fritsche HM; Tilki D; Otto W; Bolenz C; Gilfrich C; Trojan L; Herrmann E; Moritz R; Tiemann A; Müller SC; Ellinger J; Buchner A; Stief CG; Wieland WF; Höfner T; Hohenfellner M; Haferkamp A; Roigas J; Zacharias M; Nuhn P; Burger M
Urol Oncol; 2013 Oct; 31(7):1141-7. PubMed ID: 22056404
[TBL] [Abstract][Full Text] [Related]
34. Survival Benefits of Adjuvant Chemotherapy for Positive Soft Tissue Surgical Margins Following Radical Cystectomy in Bladder Cancer with Extravesical Extension.
Murthy PB; Naidu S; Davaro F; Spiess PE; Zemp L; Poch M; Jain R; Vosoughi A; Grass GD; Yu A; Sexton WJ; Gilbert SM; Li R
Curr Oncol; 2023 Mar; 30(3):3223-3231. PubMed ID: 36975458
[TBL] [Abstract][Full Text] [Related]
35. The increased risk for thromboembolism pre-cystectomy in patients undergoing neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer is mainly due to central venous access: a multicenter evaluation.
Ottosson K; Pelander S; Johansson M; Huge Y; Aljabery F; Sherif A
Int Urol Nephrol; 2020 Apr; 52(4):661-669. PubMed ID: 31745708
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.
Lancet; 1999 Aug; 354(9178):533-40. PubMed ID: 10470696
[TBL] [Abstract][Full Text] [Related]
37. The effects of neoadjuvant chemotherapy and chemo-radiation therapy on MRI staging in invasive bladder cancer: comparative study based on the pathological examination of whole layer bladder wall.
Nishimura K; Fujiyama C; Nakashima K; Satoh Y; Tokuda Y; Uozumi J
Int Urol Nephrol; 2009 Dec; 41(4):869-75. PubMed ID: 19396568
[TBL] [Abstract][Full Text] [Related]
38. Lymphovascular invasion, ureteral reimplantation and prior history of urothelial carcinoma are associated with poor prognosis after partial cystectomy for muscle-invasive bladder cancer with negative pelvic lymph nodes.
Ma B; Li H; Zhang C; Yang K; Qiao B; Zhang Z; Xu Y
Eur J Surg Oncol; 2013 Oct; 39(10):1150-6. PubMed ID: 23721764
[TBL] [Abstract][Full Text] [Related]
39. Tumor regression grade of urothelial bladder cancer after neoadjuvant chemotherapy: a novel and successful strategy to predict survival.
Fleischmann A; Thalmann GN; Perren A; Seiler R
Am J Surg Pathol; 2014 Mar; 38(3):325-32. PubMed ID: 24525502
[TBL] [Abstract][Full Text] [Related]
40. Timing cystectomy and perioperative chemotherapy in the treatment of muscle invasive bladder cancer.
Izawa JI; Chin JL; Winquist E
Can J Urol; 2006 Jun; 13 Suppl 3():48-53. PubMed ID: 16818012
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
